Trial reportAnnals of surgery2022
Extended Versus Standard Complete Mesocolon Excision in Sigmoid Colon Cancer: A Multicenter Randomized Controlled Trial.
Trial report in Annals of surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03107650 (Preoperative Prediction Model of Pathological Outcomes), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Preoperative Prediction Model of Pathological Outcomes (Mesorectum Quality and Positive Circumferential Resection Margin) in Patients With Mid-low Rectal Cancer
Who cites it
12 citing papers in PubMed, 11 citations in OpenAlex.
- Level of Vascular Ligation for Sigmoid Colon Cancer: Does It Matter? The Pina Low-T Study.Journal of surgical oncology · 2026Article
- Oncologic standards in colon cancer resection: from margins to lymph node yield and mesentery.Frontiers in surgery · 2026Review
- Non-invasive multi-phase CT artificial intelligence for predicting pre-treatment enlarged lymph node status in colorectal cancer: a prospective validation study.European radiology · 2025Article
- Navigating anatomical complexity in laparoscopic sigmoid cancer surgery: A three-dimension reconstruction protocol for intraoperative safety and efficiency.World journal of gastrointestinal surgery · 2025Article
- A snapshot on current approaches to lymphadenectomy in liver resection for intrahepatic cholangiocarcinoma: results from an international survey.Updates in surgery · 2024Article
- Comment on "Extended Versus Standard Complete Mesocolon Excision in Sigmoid Cancer. A Multicenter Randomized Controlled Trial".Annals of surgery open : perspectives of surgical history, education, and clinical approaches · 2024Article
- Inferior Mesenteric Artery Ligation Level in Rectal Cancer Surgery beyond Conventions: A Review.Cancers · 2023Review
- High tie sigmoidectomy syndrome.Techniques in coloproctology · 2023Article
- Article
- Prognostic immunogenic characteristics of iron pendant disease modifiers in colon cancer.Frontiers in immunology · 2023Article
- Does the level of inferior mesenteric artery ligation affect short-term and long-term outcomes of patients with sigmoid colon cancer or rectal cancer? A single-center retrospective study.World journal of surgical oncology · 2022Article
- Comparison of Postoperative Outcome and Prognosis Among Laparoscopic Left Colectomy and Laparoscopic Sigmoidectomy in Sigmoid Colon Cancer Patients: A Propensity Score Matching Study.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to evaluate whether extended complete mesocolic excision (e-CME) for sigmoid colon cancer improves oncological outcomes without compromising morbidity or functional results.
backgroundIn surgery for cancer of the sigmoid colon and upper rectum, s-CME removes the lymphofatty tissue surrounding the inferior mesenteric artery (IMA), but not the lymphofatty tissue surrounding the portion of the inferior mesenteric vein that does not run parallel to the IMA. Evidence about the safety and efficacy of extending CME to include this tissue is lacking.
methodsThis single-blind study randomized sigmoid cancer patients at 4 centers to undergo e-CME or s-CME. The primary outcome was the total number of lymph nodes harvested. Secondary outcomes included disease-free and overall survival at 2 years, morbidity, and bowel and genitourinary function. Clinicaltrials.gov: NCT03107650.
resultsWe analyzed 93 patients (46 e-CME and 47 s-CME). Perioperative outcomes were similar between groups. No differences between groups were found in the total number of lymph nodes harvested [21 (interquartile range, IQR, 14-29) in e-CME vs 20 (IQR, 15-27) in s-CME, P = 0.873], morbidity (P = 0.829), disease-free survival (P = 0.926), or overall survival (P = 0.564). The extended specimen yielded a median of 1 lymph node (range, 0-6), none of which were positive.Bowel function recovery was similar between arms at all timepoints. Males undergoing e-CME had worse recovery of urinary function (P = 0.026).
conclusionExtending lymphadenectomy to include the IMV territory did not increase the number of lymph nodes or improve local recurrence or survival rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.